Clinical trials: Dementia in Parkinson's Disease
Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia…
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Trial name
- NCT02708186
- Testing
- Nelotanserin
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson Disease Dementia
SHARPEN - Parkinson's Disease Dementia
The purpose of this single arm study is to evaluate the feasibility and safety of treatments with a non-invasive neuromodulation device in adults diagnosed with mild/moderate Parkinson's disease dementia (PDD).
- Trial name
- SHARPEN (NCT05987540)
- Testing
- Non-invasive brainstem stimulation
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Scion NeuroStim
Parkinson's Disease
Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy.
- Trial name
- FOG (NCT03647137)
- Testing
- Detailed motor testing, including FoG, in PD subjects
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- VA Office of Research and Development
REM Behavior Disorder, Parkinsonism
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients.
- Trial name
- NCT00745030
- Testing
- Rozerem
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Dementia, Dementia With Lewy Bodies
Monitoring Anti-Dementia Drugs by Serum Levels
The main objective of the MONANTI study is twofold: Firstly, to determine the serum concentration (SC) the anti-dementia drugs donepezil and memantine in a broadly defined clinical population of patients suffering from dementia…
- Conditions
- Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease, Dementia Alzheimers
- Trial name
- MONANTI (NCT04117178)
- Testing
- Donepezil, Memantine, Measurement of serum level of anti-dementia drug
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- Zealand University Hospital
Parkinson's Disease Dementia
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's…
- Trial name
- NCT00623103
- Testing
- Rivastigmine capsule, Rivastigmine transdermal patch
- Where
- 127 sites in United States, Argentina and 11 more
- Volunteers
- 583 people
- Sponsor
- Novartis
Mild Cognitive Impairment, Dementia
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
- Trial name
- NCT05104463
- Where
- 15 sites in United States, New Zealand
- Volunteers
- 64 people
- Sponsor
- CuraSen Therapeutics, Inc.
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease With Dementia
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
The project will investigate the effect of pharmacological and electric modulation of N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement preparation in patients with Parkinson's disease (PD).
- Trial name
- NCT01785628
- Testing
- Sarcosine Capsule
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Parkinson's Disease Dementia (PDD)
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already treated with a stable dose of a…
- Trial name
- SYNAPSE (NCT02258152)
- Testing
- SYN120
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Biotie Therapies Inc.
Parkinson's Disease, Sleep Disordered Breathing
Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease
Patients with sleep disordered breathing (SDB), also called sleep apnea, experience nighttime disrupted sleep and, because they stop breathing for short periods during the night, do not get sufficient oxygen to their brains.
- Trial name
- TAP (NCT00492115)
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of California, San Diego
Parkinson Disease Dementia, Dementia With Lewy Bodies
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
- Trial name
- NCT04831281
- Testing
- ATH-1017
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- LeonaBio
Depression, Stress, Psychological
Rural Dementia Caregiver Project
Rural caregivers face challenges of geographic isolation and lower health care access and quality. Many rural dementia caregivers experience serious health consequences due to caregiving responsibilities that can limit their…
- Conditions
- Depression, Stress, Psychological, Self Efficacy, Loneliness
- Trial name
- NCT04428112
- Testing
- Building Better Caregivers Workshop, Attention Control
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Parkinson's Disease
Cognitive Dysfunction in Parkinson's Disease
This study plans to learn more about the brain function related to thinking problems in individuals with Parkinson's disease.
- Trial name
- NCT02346708
- Testing
- Real TMS
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Colorado, Denver
Parkinson Disease
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive…
- Trial name
- NCT03713957
- Testing
- GRF6021
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Disease, Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02910102
- Testing
- RVT-101 35 mg
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson's Disease, Cognitive Impairment
Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
The purpose of this research is to evaluate the usefulness of memantine, compared to placebo (sugar pill), for the treatment of cognitive impairment in patients with idiopathic Parkinson's disease (PD) and dementia.
- Conditions
- Parkinson's Disease, Cognitive Impairment, Dementia
- Trial name
- NCT00294554
- Testing
- Memantine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University